SCHEMBL6786559

SCHEMBL6786559

CCCCCCCc1ccc(/C=C2/SC(=S)N(CCS(=O)(=O)NC(=O)c3ccc(F)cc3)C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.53
▸ FFAR1 O14842 1/20 0.51
▸ MEN1 O00255 5/20 0.47
▸ MYC P01106 1/20 0.47
▸ MAX P61244 1/20 0.47
▸ TDP1 Q9NUW8 3/20 0.46
▸ PTPN7 P35236 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PTPN12 Q05209 1/20 0.46
▸ GPR35 Q9HC97 1/20 0.46
▸ PTPN22 Q9Y2R2 1/20 0.46
▸ GPR55 Q9Y2T6 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ PSMD14 O00487 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ SAE1 Q9UBE0 1/20 0.46
▸ UBA2 Q9UBT2 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ NLRP3 Q96P20 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789175 0.92 AKR1B1 (0.51) KMT2AMEN1MYCMAXTDP1
SCHEMBL6795742 0.90 FFAR1 (0.50) KMT2AFFAR1MEN1TDP1PTPN7
SCHEMBL6789690 0.87 FFAR1 (0.49) KMT2AFFAR1MEN1MYCMAX
SCHEMBL6789677 0.87 FFAR1 (0.49) KMT2AFFAR1MEN1MYCMAX
SCHEMBL6788442 0.86 FFAR1 (0.50) KMT2AFFAR1MEN1MYCMAX
SCHEMBL6788437 0.86 FFAR1 (0.50) KMT2AFFAR1MEN1MYCMAX
SCHEMBL6786569 0.85 MAPT (0.43) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL6795751 0.80 HTR7 (0.39) KMT2AMEN1MAPTHTTPTPN1
SCHEMBL6798466 0.79 PAX8 (0.47) KMT2AMEN1TDP1PTPN7RAB9A
SCHEMBL6798462 0.79 PAX8 (0.47) KMT2AMEN1TDP1PTPN7RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 KMT2A 4348/4885FFAR1 2567/4885MEN1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback